An Insertion Mutation of ERBB2 Enhances Breast Cancer Cell Growth and Confers Resistance to Lapatinib Through AKT Signaling Pathway

Biology Open - United Kingdom
doi 10.1242/bio.047662
Full Text
Abstract

Available in full text

Date
Authors
Publisher

The Company of Biologists

Related search

AKT Signaling in ERBB2-amplified Breast Cancer

Pharmacology and Therapeutics
Pharmacology
2016English

Berberine Reverses Doxorubicin Resistance by Inhibiting Autophagy Through the PTEN/Akt/mTOR Signaling Pathway in Breast Cancer

OncoTargets and Therapy
OncologyPharmacology
2020English

B7-H3 Induces Ovarian Cancer Drugs Resistance Through an PI3K/AKT/BCL-2 Signaling Pathway

Cancer Management and Research
Oncology
2019English

Pristimerin Overcomes Adriamycin Resistance in Breast Cancer Cells Through Suppressing Akt Signaling

Oncology Letters
Cancer ResearchOncology
2016English

Targeted Lapatinib Anti-Her2/ErbB2 Therapy Resistance in Breast Cancer: Opportunities to Overcome a Difficult Problem

2020English

Loss of Nrdp1 Enhances ErbB2/ErbB3-Dependent Breast Tumor Cell Growth

Cancer Research
Cancer ResearchOncology
2006English

Combining Lapatinib (GW572016), a Small Molecule Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, With Therapeutic Anti-ErbB2 Antibodies Enhances Apoptosis of ErbB2-overexpressing Breast Cancer Cells

Oncogene
Cancer ResearchGeneticsMolecular Biology
2005English

Inhibition of Esophageal Cancer Growth Through the Suppression of PI3K/AKT/mTOR Signaling Pathway

OncoTargets and Therapy
OncologyPharmacology
2019English

PTBP1 Promotes the Growth of Breast Cancer Cells Through the PTEN/Akt Pathway and Autophagy

Journal of Cellular Physiology
Clinical BiochemistryCell BiologyPhysiology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy